Inhalation Sciences receives IRS order worth 1.9 million SEK with US pharma company
Inhalation Sciences AB (ISAB) has received an order worth 1.9 MSEK (178,000 Euros) for an Inhalation Research Service (IRS) project with a mid-sized US pharma company. The project will use ISAB’s leading in vitro dissolution and absorption module DissolvIt® to test the dissolution profiles of a new inhaled drug.
The project will test the dissolution profiles of a new drug with several formulations, both with and without excipients. It will also test if the drug’s dissolution properties are maintained when scaling up production.
ISAB’s in vitro dissolution technology - DissolvIt® - can discriminate and generate comprehensive data across several testing micronization methods, formulations and APIs.
ISAB CEO Manoush Masarrat: “It has been a great year for our IRS research services! We know that there is a growing number of mid-size pharmaceutical companies developing groundbreaking respiratory drugs like this one who have a real need for high-quality service providers with an extensive range of skills, expertise, and instruments particularly in the discovery to preclinical stage. This once again confirms our outlined strategy of focusing on research services and we are delighted to be working with our new partner on this exciting project.”
READ MORE
Explore DissolvIt’s capabilities here.
Read ISAB’s publications on DissolvIt® here.
Explore Inhalation Research Services here
For more information about Inhalation Sciences, please contact:
Manoush Masarrat, CEO
E-mail: Manoush.masarrat@inhalation.se
Mobile: +46 (0)73 628 9153
About Inhalations Sciences Sweden AB (publ)
Inhalation Sciences Sweden AB (publ) develops and commercializes world-leading instruments and services for research into inhalation. The company’s patented lab instruments PreciseInhale® and Dissolv It® enable researchers in the pharma industry to make drug pipeline decisions at an early stage, saving time and resources for R&D departments, and enables researchers in academic institutions to define how aerosols and small particles impact our lungs, and so our health, when being inhaled.
The information above was provided by Inhalation Sciences Sweden AB according to EU Market Abuse Regulations. The information was provided, through the above contact person, for publication on 23 December 2022.